Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more




  • Peri-procedural Management of New Oral Anticoagulants

    Due to the short half-life and rapid onset of action of the new oral anticoagulants (NOACs), peri-procedural anticoagulant free time intervals should be shorter than with warfarin. Thus, there is uncertainty about the use of heparin bridging.
  • Another Reason Why Sitting is Just No Darn Good For You

    Although not a life-threatening condition, benign prostatic hypertrophy (BPH) is one of the most annoying and troublesome problems that plagues aging males.
  • Clinical Briefs

    Because of its strong efficacy, long-term durability, and predictability when titrated with algorithms employed in clinical trials, basal insulin remains a mainstay of treatment for type 2 diabetes patients who are not able to attain or maintain glycemic control with oral agents alone. Because diabetes is a progressive disorder, even patients who are initially well-controlled on basal insulin will likely require “fine tuning” of their diabetes regimen, usually with agents that preferentially affect postprandial glucose levels.
  • Hydrocodone Bitartrate Extended-release Tablets (Hysingla ER) CII

    Hydrocodone is formulated to resist crushing, breaking, and dissolution and still retain some extended-release properties.
  • Clinical Briefs in Primary Care Supplement

  • Pharmacology Watch

    FDA warnings for existing drugs dominate pharmaceutical news this month. These warnings represent a new push by the FDA to regulate existing drugs for safety after they have been approved for marketing. It also comes at a time when the FDA is cleaning up its advisory committee processes, especially with regard to limiting potential conflict of interest by advisory committee members.